Key Details
Price
$1.21Annual ROE
-289.16%Beta
0.81Events Calendar
Next earnings date:
May 21, 2025Recent quarterly earnings:
Nov 13, 2024Recent annual earnings:
Mar 21, 2023Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Sept 25, 2024Analyst ratings
Recent major analysts updates
14 June '23 Benchmark
Speculative Buy22 Mar '23 Benchmark
Buy26 Sept '19 Benchmark
Speculative BuyScreeners with ORGS included
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Orgenesis doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic Leukemia
ORGS
globenewswire.com29 August 2024
Orgenesis' CD19 CAR-T therapy, ORG-101, had a complete response (CR) of 82% in adults and 93% in pediatric patients with the incidence of severe Cytokine Release Syndrome (CRS) of 2% in adult patients and 6% in pediatric patients in a real-world study
Orgenesis Announces Strategic Partnership with Harley Street Healthcare Group to Launch a State-of-the-Art Longevity & Wellness Initiative Globally
ORGS
globenewswire.com14 August 2024
The strategic alliance aims to drive new-age innovation in wellness & longevity, backed by an investment commitment of up to $10 million over 3 years into both Orgenesis and the newly formed joint venture The strategic alliance aims to drive new-age innovation in wellness & longevity, backed by an investment commitment of up to $10 million over 3 years into both Orgenesis and the newly formed joint venture
FAQ
- What is the primary business of Orgenesis?
- What is the ticker symbol for Orgenesis?
- Does Orgenesis pay dividends?
- What sector is Orgenesis in?
- What industry is Orgenesis in?
- What country is Orgenesis based in?
- When did Orgenesis go public?
- Is Orgenesis in the S&P 500?
- Is Orgenesis in the NASDAQ 100?
- Is Orgenesis in the Dow Jones?
- When was Orgenesis's last earnings report?
- When does Orgenesis report earnings?
- Should I buy Orgenesis stock now?
What is the primary business of Orgenesis?
Orgenesis is a biotechnology company focused on developing and commercializing cell and gene therapies. They aim to transform how diseases are treated by using innovative technologies to produce personalized medicine, improving patient outcomes and making advanced therapies more accessible.
What is the ticker symbol for Orgenesis?
The ticker symbol for Orgenesis is NASDAQ:ORGS
Does Orgenesis pay dividends?
No, Orgenesis does not pay dividends
What sector is Orgenesis in?
Orgenesis is in the Healthcare sector
What industry is Orgenesis in?
Orgenesis is in the Biotechnology industry
What country is Orgenesis based in?
Orgenesis is headquartered in United States
When did Orgenesis go public?
Orgenesis's initial public offering (IPO) was on 13 March 2012
Is Orgenesis in the S&P 500?
No, Orgenesis is not included in the S&P 500 index
Is Orgenesis in the NASDAQ 100?
No, Orgenesis is not included in the NASDAQ 100 index
Is Orgenesis in the Dow Jones?
No, Orgenesis is not included in the Dow Jones index
When was Orgenesis's last earnings report?
Orgenesis's most recent earnings report was on 13 November 2024
When does Orgenesis report earnings?
The next expected earnings date for Orgenesis is 21 May 2025
Should I buy Orgenesis stock now?
As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions